Healthcare / Medical DevicesNYSE
$44.26
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $78.5M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
18.6%
↑Gross Margin
85.4%
↑Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+54.2%
FCF CAGR
—
FCF margin
8.6%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $912.0M · net income $145.4M · FCF $78.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $912.0M | $912.0M | $802.8M | $624.8M | $407.9M | $233.4M | $115.4M | $82.0M | $50.6M | $28.6M |
| Net Income | $145.4M | $145.4M | $53.5M | $-21.2M | $-44.9M | $-42.0M | $-57.2M | $-33.2M | $-21.8M | $-17.5M |
| EBITDA | $64.9M | $64.9M | $42.6M | $-37.4M | $-45.7M | $-38.6M | $-55.4M | $-34.4M | $-20.0M | $-15.7M |
| EPS | 4.89 | 4.89 | 1.75 | -0.72 | -1.60 | -1.54 | -2.19 | -1.40 | — | — |
| Gross Margin | 85.4% | 85.4% | 84.7% | 84.5% | 83.8% | 85.7% | 84.7% | 83.4% | 80.1% | 78.9% |
| Operating Margin | 5.6% | 5.6% | 4.5% | -6.4% | -11.7% | -17.1% | -48.7% | -42.5% | -40.3% | -56.0% |
| Net Margin | 15.9% | 15.9% | 6.7% | -3.4% | -11.0% | -18.0% | -49.6% | -40.5% | -43.1% | -61.3% |
| Balance Sheet | ||||||||||
| Debt/Equity | — | — | — | — | — | 0.11 | 0.11 | 0.18 | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $78.5M | $78.5M | $91.1M | $1.0M | $2.5M | $-24.8M | $-55.5M | $-35.6M | $-18.9M | $-16.2M |
| Returns | ||||||||||
| ROE | 18.6% | 18.6% | 7.8% | -3.7% | -9.0% | -18.4% | -24.9% | -23.8% | -13.3% | -1319.6% |
| Growth & Yield | ||||||||||
| Revenue Growth | 13.6% | 13.6% | 28.5% | 53.2% | 74.7% | 102.3% | 40.6% | 62.2% | 77.1% | — |
| EPS Growth | 179.4% | 179.4% | 343.1% | 55.0% | -3.9% | 29.7% | -56.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-7.0%
EPS terminal req.
$3.93
Spread vs growth
186.5%
5Y implied EPS CAGR
-0.6%
EPS terminal req.
$4.75
Spread vs growth
180.0%
10Y implied EPS CAGR
4.6%
EPS terminal req.
$7.65
Spread vs growth
174.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.